To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together

Condition(s) targeted: Pharmacokinetics of Mirabegron; Healthy Subjects

Intervention: mirabegron (Drug); desipramine (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Astellas Pharma Inc

Official(s) and/or principal investigator(s):
Clinical Study Manager, Study Chair, Affiliation: Astellas Pharma Europe B.V.

The study aims to evaluate if blood levels of desipramine change whilst being dosed at the same time with daily mirabegron.

Official title: An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of the CYP2D6 Substrate Desipramine in Healthy Subjects

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Pharmacokinetics of desipramine assessed by plasma concentration while at steady state levels of mirabegron

Secondary outcome:

Monitoring of safety and tolerability through assessment of vital signs, ECG, clinical safety laboratory and adverse events

Pharmacokinetics of desipramine assessed by plasma concentration after wash-out of mirabegron

Detailed description: This is an open-label, one-sequence crossover design study to evaluate the drug-drug interaction between mirabegron and desipramine. The effect of mirabegron on the plasma concentration of desipramine will be evaluated after 13 day repeated administration. The recovery of CYP2D6 activity is also being explored by comparing the pharmacokinetic profiles of desipramine after a 2 week wash-out period.

Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Body Mass Index between 18. 5 and 30. 0 kg/m2 inclusive

- Subject is genotyped and phenotyped as an extensive metabolizer for CYP2D6

Exclusion Criteria:

- Known or suspected hypersensitivity to YM178 or any of the components of the

formulation used

- Known or suspected hypersensitivity to desipramine or any of the components of the

formulation used

- Pregnant or breast feeding within 6 months before screening assessment

- Any clinical history of major depressive disorder, cardiovascular disease, urinary

retention, glaucoma, thyroid disease and/or seizure disorder

- Any of the liver function tests (i. e. Alanine Aminotransferase (ALT), Asparate

Aminotransferase (AST) and Alkaline phosphatase) above the upper limit of normal at repeated measurements

- Any clinically significant history of asthma, eczema, any other allergic condition or

previous severe hypersensitivity to any drug (excluding non-active hay fever)

- Any clinically significant abnormality following the investigator's review of the

pre-study physical examination, ECG and clinical laboratory tests

- Abnormal pulse rate and/or blood pressure measurements at the pre-study visit as

follows: pulse rate <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg (blood pressure measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse rate will be measured automatically)

- A marked baseline prolongation of QT/QTc interval after repeated measurements of >450

ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)

SGS Aster, Paris 75015, France

Link to Results on JAPIC

Related publications:

Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.

Starting date: October 2008
Last updated: April 8, 2014